Volume 27, Number 6—June 2021
Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
|Average incidence of visits per 100 children||78||59||46||NA|
*Values are rounded to the nearest whole numbers. PCV7 was approved for use in the United States in 2000; PCV13 was approved for use in the United States in 2010. NA, not applicable; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV. †Visits expected if PCVs had not been introduced. ‡Calculated by subtracting estimated visits from expected visits.